# Sermorelin: What the Body-Composition and Growth-Hormone Studies Actually Found > Sermorelin is a GHRH(1-29) peptide that tells the pituitary to release the body's own growth hormone. A plain-English digest of the body-composition, metabolic, and GH/IGF-1 research, cited. A plain-English digest of the GH/IGF-1, body-composition, and metabolic research on GHRH(1-29), with every number traced back to the study that reported it. ## The short version Sermorelin is a small lab-made peptide — a short chain of amino acids (the building blocks of proteins). It copies the first 29 pieces of a natural hormone your brain makes called GHRH (growth hormone-releasing hormone), the signal that tells your pituitary gland to release growth hormone (GH). So sermorelin is not growth hormone itself. It is the *message* that asks the body to make its own, in the body's own natural rhythm. Researchers have studied it for decades — first in children who were not growing normally, then in older adults whose GH output had dropped with age. People today mostly ask about it for body composition: less fat, more lean muscle. The honest picture: the clearest human results are in children and in short studies of GH and IGF-1 levels. Most of the body-fat data come from a close relative of sermorelin, not sermorelin itself. What people report — including the downsides and what to watch for — is on [the effects page](/effects). ## What sermorelin actually does in the body Sermorelin works one step upstream of growth hormone. It binds the GHRH receptor (a docking site on the hormone-making cells of the pituitary gland) and switches on a chemical relay inside the cell — the cAMP/PKA pathway — that prompts those cells to release a pulse of growth hormone [1]. Because it nudges your own gland rather than pouring in outside hormone, the body's natural brakes still work: a second hormone called somatostatin and the downstream hormone IGF-1 (insulin-like growth factor 1, the messenger that carries out many of GH's effects) can still dial the signal back down [6]. That is the central appeal in the research literature — it aims to restore a *pulse*, the natural on-off rhythm of GH release, rather than flatten it. The direct human evidence is strongest where the studies are oldest. In growth-hormone-deficient children, once-daily sermorelin injections roughly doubled first-year growth speed, from about 4.1 cm/year toward 7-8 cm/year, without pushing IGF-1 to excessive levels [2]. In healthy older men around 68 years old, two weeks of twice-daily GHRH(1-29) raised 24-hour GH and IGF-1 in a dose-related way, and at the higher dose their GH and IGF-1 numbers were no longer different from those of young men [3]. ## The body-composition angle, told honestly Body composition is where the marketing and the evidence drift apart, so this site keeps them separate. Growth hormone genuinely shapes fat and muscle: its natural pulses help drive the breakdown of stored fat (lipolysis) in fasting humans [11]. And in older adults, a stabilized GHRH analog called tesamorelin — a close chemical cousin of sermorelin in the same drug class — cut percent body fat by about 7.4% over 20 weeks while raising IGF-1 by 117% within the normal range [7]. A separate randomized trial in adults with obesity and blunted GH found that the same GHRH-analog approach produced measurable changes in body composition [8]. The catch is that those fat-loss numbers come from tesamorelin and other analogs, not from controlled trials of sermorelin itself for fat loss in healthy adults [10]. So this is the line we hold throughout: the mechanism is real and the analog data are real, but using sermorelin for adult body composition or anti-aging is off-label and study-attributed, not a proven, approved outcome. The full picture is on the [sermorelin weight loss](/weight-loss) page and the [sermorelin before and after](/before-and-after) page. ## Where sermorelin stands today Sermorelin has real regulatory history. It was once an FDA-approved injectable medicine, used to help diagnose and treat growth-hormone deficiency in children. It was pulled from the U.S. market in 2008 for business reasons — not because it was found unsafe or ineffective [6]. Today it is most often prepared by compounding pharmacies, and the FDA treats it as a long-standing Category 1 bulk drug substance under its interim 503A compounding policy, with final guidance issued in January 2025. It is also worth knowing what sermorelin is *not* approved to do. There is no FDA approval for anti-aging, fat loss, or muscle building, and an Annals of Internal Medicine editorial concluded that using GH-releasing agents to fight aging is 'not yet ready for prime time' [5]. We summarize what the studies found; we do not give doses or medical advice. Start with the [Sermorelin research](/research), see what people report on the [Sermorelin effects](/effects) page, or check the [Sermorelin references](/references). --- A plain-English reading room that traces the GHRH(1-29) signal from pituitary to IGF-1 — every figure wired back to its study, the fat-loss data tagged as tesamorelin where it belongs, and the missing long-term adult evidence left openly unlit; no clinic behind the console and nothing here dosed, compounded, or sold.